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ABSTRACT A major mechanism of neurotransmitter in-
activation at catecholaminergic synapses is reuptake ofreleased
transmitter at high-affinity uptake sites on presynaptic termi-
nals. We have analyzed the anatomical distribution of site-
selective ligand binding for dopamine uptake sites in the
striatum of rat, cat, and monkey. We report here that desi-
pramine-sensitive [31H]mazindol binding sites have highly het-
erogeneous distributions in the dorsal and the ventral striatum.
In the caudate nucleus of cat and monkey, [3Hlmazindol
binding observes striosomal ordering, being reduced in strio-
somes and heightened in the extrastriosomal matrix. Some local
heterogeneity appears in the ventral caudoputamen of the rat.
Different subdivisions of the nucleus accumbens also have
different binding levels. These rmfdings suggest that some
functional effects of psychoactive drugs, such as cocaine, that
bind to the dopamine-uptake complex could be related to the
distribution of these specific uptake sites. The rindings also
raise the possibility that these distributions could result in
selective neuronal vulnerability to neurotoxins, such as 1-
methyl4-phenylpyridine (MPP+), that depend on the dopam-
ine-uptake complex for entry into neurons.
A number of powerful psychoactive drugs, including cocaine
and amphetamine, bind to sites on the presynaptic uptake
complex that constitutes a major means for neurotransmitter
inactivation at catecholaminergic synapses (1-3). Catechola-
mine-uptake sites are also potential conduits for the entry of
neurotoxins and neurotoxin precursors into catecholaminer-
gic synapses. This route is ofspecial interest in relation to the
drug-induced parkinsonian syndrome elicited by 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (4-6).
The toxic oxidative metabolite of MPTP, 1-methyl-
4-phenylpyridine (MPP+), is thought to enter catecholamine-
containing neurons by means of the uptake transport mech-
anism (7, 8). Blockade of dopaminergic and noradrenergic
uptake sites with specific blockers prevents the toxic effects
of MPTP administration on dopaminergic and noradrenergic
neurons (9-12). The precise distribution of high-affinity up-
take sites within the catecholaminergic systems of the brain
is thus important not only in relation to the normal physiology
of these pathways but also in relation to the selective effects
of drugs and environmental toxins on catecholaminergic
function.
In the experiments reported here we used in vitro ligand-
binding autoradiography with the radiolabeled catecholamine
uptake blocker [3H]mazindol in the presence of desipramine
(13, 14) to study the detailed distribution of high-affinity
dopamine uptake sites in the striatum. The results suggest
that in cat and monkey there are notable differences in the
amounts of [3H]mazindol binding in the two main tissue
compartments of the dorsal striatum, the striosomes and the
extrastriosomal matrix (15); and they suggest that different
subdivisions of the ventral striatum in rat, cat, and monkey
are also characterized by different levels of binding. These
differential anatomical distributions may help to account for
some of the functional and toxicological selectivities of drugs
acting on the mesostriatal system.
MATERIALS AND METHODS
Brains were removed from one cat, two rats, (one Sprague-
Dawley; one Wistar), one squirrel monkey, and one cyno-
molgus monkey after induction of terminal anaesthesia with
sodium pentobarbital (Nembutal). Blocks containing the stri-
atum were frozen in pulverized dry ice and were cut trans-
versely at 20 gm on a cryostat immediately or after brief
storage at -70'C. Sections cut at -12'C and thaw-mounted
onto "subbed" slides were dried at 40C in a dessicator under
vacuum, stored at -20'C for at least 2 weeks, and then
incubated according to the protocols of O'Dell and Marshall
(14) and Javitch et al. (13). For autoradiographic studies,
sections were preincubated in 50 mM Tris-HCl (pH 7.9)
containing 120 mM NaCI and 5 mM KCI at 40C (5 min), then
incubated in 50 mM Tris HCl (pH 7.9) containing 300 mM
NaCl, 5 mM KCl, either 2 nM or 15 nM [3H]mazindol (15
Ci/mmol; 1 Ci = 37 GBq; DuPont/NEN), and 0.3 ,M
desipramine (40 min, 4°C), washed in fresh buffer (two 3-min
washes, 4°C), and briefly rinsed in distilled water (10 sec,
4°C). Sections were dried under a cool airstream and applied
to 3H-sensitive film (Hyperfilm, Amersham) for 3 weeks at
-20°C. Control sections were prepared in parallel by addition
of 1 ,uM unlabeled mazindol or 30 ,uM benztropine to the
incubation medium. Controls were applied to each film along
with tritium standards ([3H]Micro-scales; Amersham). After
autoradiographic exposure, selected sections were stained
for acetylcholinesterase (AChE) or (for squirrel monkey)
butyrylcholinesterase by slightly modified Geneser-Jensen
and Blackstad protocols (15, 16) to permit detection of
striosomes. Densitometry was carried out with a BIOCOM
200 computer system (Les Ulis, France). A standard sam-
pling zone was superimposed under cursor control on video
images of [3Hlmazindol-poor zones and on adjacent [3H]maz-
indol-rich tissue identified in films of sections through the
cat's caudate nucleus. Relative grey-level values were cal-
culated for all regions sampled, and values were converted to
nCi/mg of tissue (equivalent weight) with BIOCOM software
using the [3H]Micro-scales. Mean levels of [3H]mazindol
binding were calculated for summed regions inside and
outside the [3H]mazindol-labeled compartments, and values
were compared by Student's t test (2-tailed).
Abbreviations: MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine; AChE, acetylcholinesterase.
*To whom reprint requests should be addressed.
9020
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Proc. Natl. Acad. Sci. USA 86 (1989) 9021
RESULTS
Dense [3H]mazindol binding appeared in the striatum in all
brains under normal incubation conditions and binding was
absent in control sections. At mid-anterior levels through the
cat's striatum, binding in the caudate nucleus was highly
patterned, with circumscribed zones of relatively reduced
binding punctuating otherwise densely labeled fields (Fig.
1A). Most of the [3H]mazindol-poor zones could be identified
as striosomes when the autoradiographic images were com-
pared with AChE staining patterns developed from the same
sections: the shapes and positions of the zones of low
[3H]mazindol binding matched those ofthe AChE-poor zones
(Fig. 1). Even in single films, the degree of patterning of
[3H]mazindol was not equivalent at all anteroposterior and
dorsoventral levels of the striatum. Binding tended to be
more homogeneous caudally and dorsolaterally in the cau-
date nucleus, as did the AChE staining, and little patterning
was visible in the putamen. Occasionally, regions of rela-
tively heightened binding were evident. Correspondents for
these were not identified in AChE stains.
Pockets of reduced [3H]mazindol binding were also ob-
served in the caudate nucleus of the squirrel monkey (Fig. 2)
and cynomolgus monkey (Fig. 3), but the autoradiography
was not as crisp as in the cat and not every AChE-poor
striosome could be matched to a [3H]mazindol-poor zone.
Even so, it was possible in both primate species to confirm
correspondence of many [3H]mazindol-poor zones with stri-
osomes identified histochemically in the same sections after
autoradiography. Patterns of binding were quite diffuse in the
putamen. No clear patchiness in [3H]mazindol binding was
evident in the central and dorsal regions of rat's caudoputa-
men, but ventrally in the caudoputamen some zones of low
binding did appear.
Densitometry performed for the cat's caudate nucleus
(Table 1) indicated that the mean binding in the [3H]mazindol-
poor zones was 51.23% of the mean binding in adjacent
matrix tissue (n = 63 sampled zones in four sections).
There were marked differences in the intensity of binding
in different parts of the nucleus accumbens. As shown in Fig.
4 for the cat, binding was dense rostrolaterally but was very
weak caudally and medially. Comparable variations were
FIG. 2. [3H]Mazindol binding in striatum of squirrel monkey.
Zones ofreduced binding in the caudate nucleus (matching histochem-
ically identified striosomes, data not shown) were mainly found in the
ventral half of the nucleus (example at asterisk). Slight heterogeneity
is also evident in binding in putamen (see asterisk), and subdivision-
specific variations in binding are present in the nucleus accumbens-
ventral striatum. From case SQDAR-4. Photograph was printed
directly from autoradiographic film. CN, caudate nucleus; P. puta-
men; IC, internal capsule; NA, nucleus accumbens. (Bar = 1 mm.)
present in the monkeys, and in the rat the "shell" subdivision
of the nucleus accumbens (17) had much reduced binding
compared to that of the core subdivision.
FIG. 1. [3H]Mazindol binding
(A) and AChE activity (B) in serial
transverse sections through the
striatum of an adult cat. Photo-
graph in A was directly printed
from film; photograph in B is neg-
ative-image print. Prominent
patches of reduced (3H]mazindol
binding appear in the central part
of the caudate nucleus. These cor-
respond to the AChE-poor strio-
somes visible in B (examples at
asterisks). From case CDAR-12.
CN, caudate nucleus; P. putamen;
IC, internal capsule; AC, anterior
commissure; NA, nucleus accum-
*,,.^bens. (Bar = 1 mm.)
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FIG. 3. Sector of medial caudate nucleus
of cynomolgus monkey illustrating corre-
spondence (see asterisks) between zones of
reduced [3H]mazindol binding (A) and zones
of reduced AChE-staining (B). Note similar-
ity in size and shape of zones in the two
images. (A) Printed directly from film. (B)
Printed in negative image. From case MR-1.
Sections are 60 ,um apart. CN, caudate nu-
cleus; P, putamen; IC, internal capsule; NA,
nucleus accumbens. (Bar = 1 mm.)
DISCUSSION
These observations have implications of at least two types.
First, the findings indicate that pharmacologic treatments
affecting the dopamine uptake mechanism may have differ-
ential effects on the striosome and matrix subdivisions of the
dorsal striatum and on distinct subdivisions of the ventral
striatum. Second, the findings suggest that entry of potential
toxins into dopamine-containing fibers in the striatum could
be different for these striatal compartments.
For the dorsal striatum the differences in [PH]mazindol
binding were clearest in the caudate nucleus and, among
species, were sharpest in the cat and only occasionally
detectable, and then only ventrally, in the rat's caudoputa-
men. The lower numbers of uptake sites available for the
binding of [3H]mazindol in striosomes suggest that there
either are fewer dopamine-containing terminals in this striatal
compartment or are fewer sites per terminal in striosomes
than in the extrastriosomal matrix, or, conceivably, that the
sites in the two striatal compartments have different molec-
ular conformations although both bind [3H]mazindol. There
is no direct evidence yet to settle this issue. Both striosomes
and matrix are richly innervated by fibers from the midbrain,
but different cell groups within the nigral complex innervate
the two striatal compartments to different extents (18-20).
Striosomes have lower tyrosine hydroxylase-like immuno-
reactivity than the extrastriosomal matrix (21, 22). This
distinction, like that for the [3H]mazindol binding reported
here, could reflect metabolic differences between striosome-
directed and matrix-directed fibers rather than differences in
the respective densities of such fibers. Olson et al. (23) have
proposed such metabolic differences on the basis of experi-
ments with tyrosine hydroxylase inhibitors.
The compartmental selectivity in [3H]mazindol binding in
the caudate nucleus documented here provides additional
evidence for fundamental differences between dopaminergic
mechanisms in striosomes and matrix as judged not only by
Di-selective ligand binding [heightened in striosomes (24)] and
Table 1. Densitometry on [3H]mazindol binding in the caudate
nucleus of the cat
[3H]Mazindol bound, Ci/mg of tissue matrix
Section Striosome Matrix ratio, %
763 10.60 ± 2.69* (10) 22.71 ± 2.30 (8) 46.7
643 13.66 ± 1.98* (8) 22.45 ± 3.06 (5) 60.8
715 10.60 ± 2.69* (10) 22.70 ± 2.30 (8) 46.7
571 11.85 ± 3.91* (6) 22.67 ± 2.63 (6) 52.2
Total 11.73 ± 3.36 (34) 22.89 ± 3.55 (29) 51.23
Higher section numbers are for more rostral sections. Values for[3H]mazindol binding to striosome and matrix are mean ± SD.
Numbers in parenthesis refer to n.
*Significantly different from binding in matrix at P < 0.0001.
D2-selective ligand binding [heightened in the matrix (25)] but
also by presynaptic markers. Interestingly, all of these mark-
ers display greater compartmental selectivity in the caudate
nucleus than in the putamen and are not as clearly compart-
mental in distribution in the rat (if they are at all) as they are
in carnivores and primates. Amphetamine treatment in the rat
has, however, been found to induce patchy anatomical distri-
butions of transmitter-related compounds, including (presyn-
aptic) tyrosine hydroxylase-immunoreactive patches (26) and
(postsynaptic) dynorphin immunoreactive patches (27).
If synpatic release of dopamine is mainly from the newly
synthesized pool of transmitter (28), the difference in number
of uptake sites shown here for striosomes and matrix (about
50% maximum detected difference) might not be reflected
functionally in these normally slow-firing neurons. Clearly,
however, with intense firing and transmitter release or under
the influence of drugs inducing massive transmitter release,
differences in the capacity for transmitter clearance by re-
uptake could be functionally significant. Uptake-site block-
ade by agents such as cocaine could also have markedly
different effects on striosomes and matrix. Interpretation of
such differences is now constrained by lack of information
about the distribution of uptake sites on single terminals in
striosomes and matrix; but given that the [3H]mazindol
binding site has been directly related to the [3H]cocaine
binding site on the dopamine uptake-site complex (2), the
present results suggest that striosome-matrix differences in
uptake-site distribution should be taken into account in
addition to compartmental differences in D1/D2-binding-site
ratios in analyzing drug effects on the nigrostriatal system.
There are considerable dose-response differences in the
behavioral effects of drugs affecting catecholamine uptake
sites, and some of these relate to the different expression of
behaviors thought to be mediated preferentially by sensory-
motor and limbicohypothalamic mechanisms (2, 29, 30). The
contrasting pre- and postsynaptic character of the dopamine
innervations of striosomes and matrix could be essential to an
understanding of these drug effects, for striosomes are pref-
erentially related to a subset of limbic pathways and project
to the substantia nigra, whereas the extrastriosomal matrix is
linked to sensorimotor regions and other limbic pathways and
projects preferentially into pallidothalamic and nigrotectal
pathways (for review, see ref. 31).
For the dopamine-containing mesolimbic system, there
also were striking regional inhomogeneities in uptake-site
distribution, and these regional differences were at least as
marked as those for striosomes and matrix in the dorsal
striatum. Marshall (32) has already noted lower levels of[3H]dopamine uptake and [3H]mazindol binding in the ventral
than in the dorsal striatum in the rat, and the present findings
extend his observations by suggesting that different parts of
the nucleus accumbens have different levels of [3H]mazindol
binding. Selective functional effects of drugs would be ex-
Proc. Natl. Acad. Sci. USA 86 (1989)
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FIG. 4. Transverse sections at rostral (A)
and caudal (B) levels through the ventral
striatum of the cat illustrating the strong
[3H]mazindol binding in anterior and lateral
parts of the nucleus accumbens and olfac-
tory tubercle and the weak binding in caudal
and medial parts of the ventral striatum. The
sections were approximately 960 ,um apart.
From case CDAR-4. Photographs were
printed directly from the autoradiographic
film. NA, nucleus accumbens; Olf T, olfac-
tory tubercle; CN, caudate nucleus; IC, in-
ternal capsule; AC, anterior commissure.
(Bar = 1 mm.)
pected according to these differences as well (see refs. 17 and
33). As in the dorsal striatum, there is no obvious relation
between the degree of [3H]mazindol binding and known
intensities of total innervation by dopamine-containing fi-
bers; for example, the dopamine-containing innervation is
intense in the medial "shell" of the nucleus (17), where
[3H]mazindol binding is relatively weak.
The present observations have special significance in sug-
gesting that different subdivisions of the nigrostriatal and
mesolimbic systems might have different vulnerabilities to
MPTP intoxication. In fact, there is a striking similarity
between the striosomal patterning of [3H]mazindol binding
shown here for the cat and the pattern of fiber degeneration
observed by Wilson et al. (34) and Turner et al. (35) in dogs
acutely exposed to MPITP. At 8-14 days after MPTP injection,
these authors found intense degeneration of fibers in the
extrastriosomal matrix with relative sparing of fibers in the
striosomes. They also describe the striosomal pattern as being
clearest in the caudate nucleus at rostral and midanterior levels
and illustrate fiber degeneration in the nucleus accumbens
mainly in the lateral rather than the medial part of the nucleus.
Given the findings presented here, serious consideration
should be given to the possibility that such differential
patterns of MPTP-induced fiber degeneration might reflect
local inhomogeneities in uptake-site distribution within the
striatum, just as, in general, the greater vulnerability of more
dorsal than more ventral striatal regions might be related to
gradients of uptake-site distribution (27). The possibility that
local variations in uptake-site distribution within the striatum
constrain the level of degeneration induced by acute expo-
sure to MPTP is in accord with the finding that intrastriatal
administration of MPTP can induce degenerative changes in
neurons in the midbrain (36, 37). Such differential vulnera-
bility of fiber terminals could account for patterns of partial
sparing of midbrain neurons seen with dose schedules pro-
ducing submaximal damage to the system (38, 39). To the
extent that the MPTP model relates to other forms of par-
kinsonism, the compartmental distributions of uptake sites
described here could be important in constraining patterns of
mesencephalic neuronal loss in these disorders as well (40).
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